These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36371249)

  • 1. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach.
    Drożdż K; Nabrdalik K; Kwiendacz H; Hendel M; Olejarz A; Tomasik A; Bartman W; Nalepa J; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2022 Nov; 21(1):240. PubMed ID: 36371249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
    Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
    Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD.
    Li Z; Gong R; Chu H; Zeng J; Chen C; Xu S; Hu L; Gao W; Zhang L; Yuan H; Cheng Z; Wang C; Du M; Zhu Q; Zhang L; Rong L; Hu X; Yang L
    Atherosclerosis; 2024 May; 392():117526. PubMed ID: 38581738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of the correlation between metabolic-associated fatty liver disease and coronary plaque pattern.
    Zhang Z; Zheng M; Lei H; Jiang Z; Chen Y; He H; Zhao G; Huang H
    Sci Rep; 2023 May; 13(1):7224. PubMed ID: 37142746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants.
    Alaa AM; Bolton T; Di Angelantonio E; Rudd JHF; van der Schaar M
    PLoS One; 2019; 14(5):e0213653. PubMed ID: 31091238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning model for cardiovascular disease prediction in patients with chronic kidney disease.
    Zhu H; Qiao S; Zhao D; Wang K; Wang B; Niu Y; Shang S; Dong Z; Zhang W; Zheng Y; Chen X
    Front Endocrinol (Lausanne); 2024; 15():1390729. PubMed ID: 38863928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
    Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
    HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
    Sharma D; Gotlieb N; Farkouh ME; Patel K; Xu W; Bhat M
    J Am Heart Assoc; 2022 Jan; 11(1):e022576. PubMed ID: 34927450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial Use of Machine Learning and Logistic Regression for Predicting Carotid Plaque Risk Among 5.4 Million Adults With Fatty Liver Disease Receiving Health Check-Ups: Population-Based Cross-Sectional Study.
    Deng Y; Ma Y; Fu J; Wang X; Yu C; Lv J; Man S; Wang B; Li L
    JMIR Public Health Surveill; 2023 Sep; 9():e47095. PubMed ID: 37676713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
    Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
    Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
    Zhou XD; Targher G; Byrne CD; Somers V; Kim SU; Chahal CAA; Wong VW; Cai J; Shapiro MD; Eslam M; Steg PG; Sung KC; Misra A; Li JJ; Brotons C; Huang Y; Papatheodoridis GV; Sun A; Yilmaz Y; Chan WK; Huang H; Méndez-Sánchez N; Alqahtani SA; Cortez-Pinto H; Lip GYH; de Knegt RJ; Ocama P; Romero-Gomez M; Fudim M; Sebastiani G; Son JW; Ryan JD; Ikonomidis I; Treeprasertsuk S; Pastori D; Lupsor-Platon M; Tilg H; Ghazinyan H; Boursier J; Hamaguchi M; Nguyen MH; Fan JG; Goh GB; Al Mahtab M; Hamid S; Perera N; George J; Zheng MH
    Hepatol Int; 2023 Aug; 17(4):773-791. PubMed ID: 37204656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.